Sponsored · Video
WellMarker Bio Accelerates the Development of Predictive Biomarker-based Anticancer Drugs
Dong-Hoon Jin, Founder and CEO of WellMarker Bio Co., Ltd (WMBIO), speaks at BIO-Europe 2019 in Hamburg about their programs focused on predictive biomarker-based anticancer drugs to identity novel targets. WMBIO is a spin-off company from Seoul Asan Medical Center, which is the biggest and most renowned hospital in the Republic of Korea. The company specializes in discovering and defining novel predictive biomarkers and utilizes these to develop ideal matching drug candidates. As a result, WMBIO can shorten the lead time, reduce the development cost, and increase the success rate in first-in-class anti-cancer drugs.